Skip to content 
In a major development in pain treatment, the U.S. Food and Drug Administration (FDA) has approved a new non-opioid medication called Journavx (generic name suzetrigine) for adults experiencing moderate to severe acute pain. This represents the first new class of non-opioid pain medicine approved in more than two decades, highlighting ongoing efforts to expand safe alternatives to opioids in clinical care.
What Makes Journavx Different?
Unlike traditional opioids, which act on brain receptors and carry a risk of dependence and addiction, Journavx works by selectively blocking sodium channels (specifically NaV1.8) on pain-sensing nerve cells in the peripheral nervous system. This mechanism interrupts painful signals before they reach the spinal cord and brain, providing analgesic effects without engaging the pathways responsible for addiction.
Because it does not bind to opioid receptors, Journavx is not classified as a controlled substance and is not expected to have addictive potential, offering a significant advantage for patients and clinicians seeking to reduce reliance on opioids when managing acute pain.
Who Might Benefit?
Journavx is approved specifically for short-term acute pain—including surgical pain, injury-related pain, or other sudden intense pain episodes. It is not currently approved for chronic pain conditions, and its use beyond 14 days has not been studied.
Clinical trials showed that the drug significantly reduced pain intensity following surgical procedures, such as abdominoplasty (tummy tuck) and bunionectomy, compared with placebo.
Safety and Side Effects
Common side effects reported in studies include itching, muscle spasms, rash, and elevated creatine phosphokinase levels—none of which involve the sedation or respiratory depression risks associated with opioids. Because Journavx’s safety and effectiveness beyond acute pain have not been established, clinicians should use it within its approved indications and duration.
What This Means for Pain Care
The approval of Journavx marks an important milestone in the pursuit of non-opioid pain management tools. It gives healthcare providers another option for patients who may be at risk for opioid-related side effects, dependence, or who simply prefer alternatives when appropriate.
Experts also note that broader access to non-opioid therapies like Journavx could play a role in addressing the ongoing opioid crisis by reducing initial exposure to addictive medications for acute pain.
Final Thoughts
While clinicians and pain specialists continue to refine multimodal pain management strategies, the introduction of Journavx offers a promising non-opioid option for select patients with acute pain. As with all medications, treatment decisions should be individualized based on clinical circumstances, patient history, and current evidence.
For patients interested in learning whether Journavx might be appropriate for their pain care plan, we encourage discussing this option with your provider to understand potential benefits, risks, and insurance coverage.
